108 related articles for article (PubMed ID: 25707497)
1. Prediction of desmoid tumor progression using miRNA expression profiling.
Dufresne A; Paturel M; Alberti L; Philippon H; Duc A; Decouvelaere AV; Cassier P; Blay JY
Cancer Sci; 2015 May; 106(5):650-5. PubMed ID: 25707497
[TBL] [Abstract][Full Text] [Related]
2. Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology.
Dufresne A; Alberti L; Brahmi M; Kabani S; Philippon H; Pérol D; Blay JY
BMC Cancer; 2014 Aug; 14():632. PubMed ID: 25174682
[TBL] [Abstract][Full Text] [Related]
3. Gene Expression Profiling of Desmoid Tumors by cDNA Microarrays and Correlation with Progression-Free Survival.
Salas S; Brulard C; Terrier P; Ranchere-Vince D; Neuville A; Guillou L; Lae M; Leroux A; Verola O; Jean-Emmanuel K; Bonvalot S; Blay JY; Le Cesne A; Aurias A; Coindre JM; Chibon F
Clin Cancer Res; 2015 Sep; 21(18):4194-200. PubMed ID: 25878329
[TBL] [Abstract][Full Text] [Related]
4. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).
Kasper B; Gruenwald V; Reichardt P; Bauer S; Rauch G; Limprecht R; Sommer M; Dimitrakopoulou-Strauss A; Pilz L; Haller F; Hohenberger P
Eur J Cancer; 2017 May; 76():60-67. PubMed ID: 28282612
[TBL] [Abstract][Full Text] [Related]
5. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
[TBL] [Abstract][Full Text] [Related]
6. Desmoid-type fibromatoses involving the brachial plexus: treatment options and assessment of c-KIT mutational status.
Seinfeld J; Kleinschmidt-Demasters BK; Tayal S; Lillehei KO
J Neurosurg; 2006 May; 104(5):749-56. PubMed ID: 16703880
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinib.
Kasper B; Dimitrakopoulou-Strauss A; Pilz LR; Strauss LG; Sachpekidis C; Hohenberger P
Biomed Res Int; 2013; 2013():389672. PubMed ID: 23762842
[TBL] [Abstract][Full Text] [Related]
8. Control of aggressive fibromatosis by treatment with imatinib mesylate: a step forward?
Ravaioli A; Nicoletti S; Tamburini E; Papi M
J Cancer Res Clin Oncol; 2009 Feb; 135(2):325-6. PubMed ID: 18825412
[TBL] [Abstract][Full Text] [Related]
9. Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor.
Verschoor AJ; Cleton-Jansen AM; Wijers-Koster P; Coffin CM; Lazar AJ; Nout RA; Rubin BP; Gelderblom H; Bovée JV
Am J Surg Pathol; 2015 Dec; 39(12):1701-7. PubMed ID: 26414222
[TBL] [Abstract][Full Text] [Related]
10. Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).
Kasper B; Gruenwald V; Reichardt P; Bauer S; Hohenberger P; Haller F
Ann Surg Oncol; 2016 Jun; 23(6):1924-7. PubMed ID: 26861905
[TBL] [Abstract][Full Text] [Related]
11. Paraneoplastic insulin resistance syndrome in advanced aggressive fibromatosis (desmoid tumor) treated by imatinib mesylate.
Folli F; Galimberti G; Pastore M; Davalli AM; Bosi E
Diabetes Care; 2006 Sep; 29(9):2178-80. PubMed ID: 16936177
[No Abstract] [Full Text] [Related]
12. Desmoid-type fibromatosis.
Bertucci F; Gonçalves A; Viens P; Monges G; Dubreuil P
J Neurosurg; 2007 Aug; 107(2):473-5; author reply 475. PubMed ID: 17695408
[No Abstract] [Full Text] [Related]
13. Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study.
Kwon J; Lee JH; Lee YH; Lee J; Ahn JH; Kim SH; Kim SH; Kim TI; Yun KH; Park YS; Kim JE; Lee KS; Choi JK; Kim HS
Cancer Res Treat; 2022 Oct; 54(4):1240-1255. PubMed ID: 35038826
[TBL] [Abstract][Full Text] [Related]
14. Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis.
Dufresne A; Bertucci F; Penel N; Le Cesne A; Bui B; Tubiana-Hulin M; Ray-Coquard I; Cupissol D; Chevreau C; Perol D; Goncalves A; Jimenez M; Bringuier PP; Blay JY
Br J Cancer; 2010 Aug; 103(4):482-5. PubMed ID: 20664593
[TBL] [Abstract][Full Text] [Related]
15. The role of imatinib mesylate in adjuvant therapy of extra-abdominal desmoid tumors.
Ioannou M; Demertzis N; Iakovidou I; Kottakis S
Anticancer Res; 2007; 27(2):1143-7. PubMed ID: 17465254
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib.
Kasper B; Dimitrakopoulou-Strauss A; Strauss LG; Hohenberger P
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1876-82. PubMed ID: 20559633
[TBL] [Abstract][Full Text] [Related]
17. Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors.
Skubitz KM; Manivel JC; Clohisy DR; Frolich JW
Cancer Chemother Pharmacol; 2009 Aug; 64(3):635-40. PubMed ID: 19404642
[TBL] [Abstract][Full Text] [Related]
18. Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
Koskenvesa P; Kreutzman A; Rohon P; Pihlman M; Vakkila E; Räsänen A; Vapaatalo M; Remes K; Lundán T; Hjorth-Hansen H; Vakkila J; Simonsson B; Mustjoki S; Porkka K
Eur J Haematol; 2014; 92(5):413-20. PubMed ID: 24372965
[TBL] [Abstract][Full Text] [Related]
19. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
Mace J; Sybil Biermann J; Sondak V; McGinn C; Hayes C; Thomas D; Baker L
Cancer; 2002 Dec; 95(11):2373-9. PubMed ID: 12436445
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.
Chugh R; Wathen JK; Patel SR; Maki RG; Meyers PA; Schuetze SM; Priebat DA; Thomas DG; Jacobson JA; Samuels BL; Benjamin RS; Baker LH;
Clin Cancer Res; 2010 Oct; 16(19):4884-91. PubMed ID: 20724445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
